Brain Cancer Clinical Trials in Pittsburgh

Showing 161-180 of 181 trials

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

NCT00378235

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13-receptor positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells.

Recurrent Malignant Glioma

INSYS Therapeutics Inc

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +7 more locations

COMPLETED< 1 mile

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

NCT00003096

RATIONALE: Analyzing the number and structure of genes found in a child's cancer cells may help doctors improve methods of diagnosing and treating children with brain tumors. PURPOSE: This clinical trial is studying the number and structure of genes in cancer cells of children with brain tumors.

Brain TumorsCentral Nervous System Tumors

Children's Oncology Group88 participantsStarted Dec 1996

Phoenix, Arizona, United States • Downey, California, United States • Loma Linda, California, United States +58 more locations

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

Brain Cancer Trials in Other Cities

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme

Other Conditions in Pittsburgh